Industry News

• Thermo Fisher Scientific reports second quarter 2017 results  Thermo Fisher Scientific reported GAAP operating income for the 2017 second quarter grew to $752 million, versus $638 million in the second quarter of 2016. Revenue for the 2017 second quarter grew 10% to $4.99 billion in 2017, versus $4.54 billion in the same 2016 quarter.
  July 26, 2017  
• Gap In perceived and actual rates of prescription drug abuse found among college students   A preliminary analysis of data from research conducted by the University of Washington reveals a gap in perception and reality when it comes to prescription stimulant misuse, abuse and diversion on U.S. college campuses. The research surveyed 2,989 students at seven U.S. universities.
  July 26, 2017  
• Ophthotech reports second quarter 2017 financial results  Ophthotech reported a net loss for the 2017 second quarter of $22.2 million, or ($0.62) per diluted share,versus a net loss of $29.9 million, or ($0.85) per diluted share, for the same 2016 period. Revenue was $1.7 million for the 2017 second quarter versus $28.2 million for the prior year period.
  July 26, 2017  
• Pacira announces publication of phase 4 study of EXPAREL in The Journal of Arthroplasty  Pacira announced publication of its Phase 4 PILLAR study of EXPAREL® in total knee arthroplasty. The results demonstrate a statistically significant reduction in opioid requirements and pain scores for EXPAREL admixed with bupivacaine HCl versus bupivacaine HCl alone.
  July 26, 2017  
• Argos reports immunogenicity results of AGS-004 in HIV program  Argos announced immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. The study achieved its primary endpoint, with all six patients demonstrating a positive immune response, defined as a greater than 2-fold increase from baseline.
  July 26, 2017  
• Surmodics receives IDE approval to initiate pivotal trial of the SurVeilTM DCB  Surmodics announced it has received an investigational device exemption from the FDA to initiate a pivotal clinical trial of the SurVeil™ drug-coated balloon. The randomized trial will evaluate the SurVeil DCB for treatment for PAD in the upper leg compared to the Medtronic IN.PACT® Admiral® DCB.
  July 26, 2017  
• Oragenics announces completion of second closing of $3.0 million preferred stock placment  Oragenics announced that it has completed the second closing contemplated by the previously disclosed securities purchase agreement with three accredited investors to purchase $3.0 million of Series A convertible preferred stock at a price of $0.25 per share .
  July 26, 2017  
• Baxter reports second-quarter 2017 results   Baxter reported GAAP income from continuing operations of $264 million, or $0.48 per diluted share for the 2017 second quarter. Worldwide sales totaled $2.6 billion, an increase of 1 percent on a reported basis compared to the prior-year period.
  July 26, 2017  
• Bristol-Myers Squibb’s ORENCIA® (abatacept) receives EC approval for treatment of PsA  Bristol-Myers Squibb announced the EC has approved ORENCIA alone or in combination with methotrexate for treatment of active Psoriatic Arthritis in adult patients for whom the response to previous disease-modifying antirheumatic drug therapy has been inadequate.
  July 26, 2017  
• LabCorp announces record results in the second quarter of 2017   LabCorp reported operating income for the 2017 second quarter was $336.0 million, or 13.4% of net revenue, versus $365.5 million, or 15.3%, in the prior year period. Net revenue for the 2017 second quarter was $2.50 billion, an increase of 4.9% compared to $2.38 billion in the same 2016 quarter.
  July 26, 2017  

   (next 10 articles)